Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows: - cardiac surgery devices (53.5%); - medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.; - sanguine transfusion equipments (17.9%). Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).

Employees

30,591

Sector

Medical Equipment, Supplies & Distribution

Calendar

05/02/2025 - Q3 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
06/12/24	3,080.00 ¥	-1.19%	2,205,400
05/12/24	3,117.00 ¥	+0.58%	2,376,700
04/12/24	3,099.00 ¥	0.00%	2,752,200
03/12/24	3,099.00 ¥	+1.01%	3,828,700
02/12/24	3,068.00 ¥	+0.56%	2,800,200

Delayed Quote Japan Exchange, December 06, 2024 at 06:30 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart TERUMO-CORPORATION

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,080.00JPY

Average target price

3,316.67JPY

Spread / Average Target

+7.68%

Consensus

Profit revisions

estimates-change-chart TERUMO-CORPORATION

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart TERUMO-CORPORATION

Company calendar

Market Closed - Japan Exchange Other stock markets 06:30:00 06/12/2024 GMT			5-day change	1st Jan Change
3,080.00 ^JPY	-1.19%		+0.95%	+33.28%

12-04	Terumo Buys Back 3.2 Million Shares in November	MT
12-03	Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support Catheter	CI

Capitalization	4,560B 30.42B 28.78B 26.68B 23.86B 43B 2,576B 47.6B 332B 123B 1,058B 114B 112B	P/E ratio 2025 *	34.8x	P/E ratio 2026 *	30x
Enterprise value	4,530B 30.22B 28.6B 26.51B 23.71B 42.72B 2,559B 47.29B 330B 122B 1,051B 114B 111B	EV / Sales 2025 *	4.44x	EV / Sales 2026 *	4.08x
Free-Float	96.6%	Yield 2025 *	0.84%	Yield 2026 *	0.99%

Terumo Buys Back 3.2 Million Shares in November	12-03	MT
Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support Catheter	12-03	CI
Terumo Corporation, Q2 2025 Earnings Call, Nov 07, 2024	11-07
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	11-07	CI
Japan Lifeline Co., Ltd. Signs Five-Year Exclusive Distribution Agreement with Terumo Corporation for Proprietary Liver Cancer Ablation System	10-31	CI
NAMSA and TERUMO Announce Strategic Outsourcing Partnership	10-15	CI
Terumo Spends 2.24 Billion Yen in September Buybacks	10-03	MT
Tranche Update on Terumo Corporation's Equity Buyback Plan announced on August 29, 2024.	10-02	CI
Terumo Finalizes Offer Price, Other Details for Secondary Share Offering	09-11	MT
Jefferies Adjusts Terumo's Price Target to 3,500 Yen From 3,350 Yen, Keeps at Buy	09-02	MT
Terumo Plans Secondary Offering, Buyback and Cancellation of Shares; Shares Down 4%	08-30	MT
Terumo Corporation announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.	08-29	CI
Japan's Terumo to Make Secondary Share Offering in Overseas Markets	08-29	DJ

Jefferies Adjusts Terumo's Price Target to 3,500 Yen From 3,350 Yen, Keeps at Buy	09-02	MT
Terumo to Allocate 4,048 Share Warrants	08-05	MT
Terumo Sets Terms for Share Warrants as Stock Options	07-11	MT
Jefferies Adjusts Terumo’s Price Target to 6,700 Yen From 5,300 Yen, Keeps at Buy	03-13	MT
Jefferies Adjusts Terumo's Price Target to 5,300 Yen From 4,500 Yen, Keeps at Buy	01-04	MT

Terumo Corporation Share Price

Equities

4543

JP3546800008

Medical Equipment, Supplies & Distribution

Valuation: Terumo Corporation

Chart: Terumo Corporation

Latest news: Terumo Corporation

Last Transcript: Terumo Corporation

Analysts' recommendations: Terumo Corporation

Press Releases: Terumo Corporation

News in other languages: Terumo Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Terumo Corporation

ETFs: Terumo Corporation

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Terumo : Multi-Center Superiority Clinical Trial, Supported by Terumo Blood and Cell Technologies, Aims to Significantly Reduce Complications From Acute Chest Syndrome in Adult Sickle Cell Disease Patients	12-04	PU
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation	11-27	AQ
Terumo : Blood and Cell Technologies Unlocks New Chapter of Localization in China to Facilitate Blood and Cell Treatment Options for Patients	11-13	PU
Terumo : Blood and Cell Technologies Merges Therapeutics Units to Enhance Patient Care Across Treatment JourneyNew Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to unify therapeutic apheresis and cell and gene therapy expertise to expand therapeutic possibilities	11-13	PU
Terumo : Q&A Session at the Financial Results Briefing for the Second Quarter of Fiscal Year Ending March 31, 2025	11-08	PU

NAMSA und TERUMO kündigen strategische Outsourcing-Partnerschaft an	10-16
MicroVention firmiert in Terumo Neuro um – Ausdruck eines erweiterten Fokus und strategischen Wachstums	09-12
MicroVention cambia su marca a Terumo Neuro – Refleja un enfoque ampliado y un crecimiento estratégico	09-12
Stryker Corporation: Principal actor en dispositivos médicos	07-17
Stryker Corporation: un'azienda leader nei dispositivi medici	07-13

1 day	-1.19%
1 week	+0.95%
Current month	+0.95%
1 month	+3.69%
3 months	+16.40%
6 months	+14.35%
Current year	+33.28%

Director	Title	Age	Since
Naoki Muto DFI	Director of Finance/CFO	-	-
Miho Mizuguchi CMP	Compliance Officer	-	-
Kazuhisa Senshu CTO	Chief Tech/Sci/R&D Officer	-	-

Manager	Title	Age	Since
Shinjiro Sato BRD	Director/Board Member	64	31/05/2014
Kyo Nishikawa BRD	Director/Board Member	65	20/06/2019
Shouji Hatano BRD	Director/Board Member	65	31/05/2016

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS TOPIX-17 ELECTRIC APPLIANCES & PRECISION INSTRUMENTS ETF - JPY	2.24%	30 M€	+14.48%
DAIWA ETF-NIKKEI 225 ETF - JPY	1.94%	29,408 M€	+17.06%	-
SMDAM NIKKEI225 ETF - JPY	1.93%	864 M€	+16.97%
MAXIS NIKKEI 225 ETF - JPY	1.90%	14,787 M€	+16.71%	-
NOMURA NIKKEI 225 EXCHANGE TRADED FUND ETF - JPY	1.82%	64,976 M€	+16.91%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
TERUMO CORPORATION	-1.19%	+0.95%	+29.30%	+33.45%	30.42B
ABBOTT LABORATORIES	+0.01%	-2.67%	+10.16%	-12.73%	201B
MEDTRONIC PLC	-0.15%	-2.92%	+6.29%	-23.79%	108B
BECTON, DICKINSON AND COMPANY	-1.00%	-0.85%	-5.75%	-10.61%	63.61B
HOYA CORPORATION	+0.82%	+5.32%	+21.98%	+13.04%	47.07B
CENCORA, INC.	-0.37%	-3.24%	+21.30%	+104.72%	47.05B
DEXCOM, INC.	-1.52%	-0.35%	-34.10%	-40.72%	30.36B
WEST PHARMACEUTICAL SERVICES, INC.	+1.35%	-0.98%	-5.96%	-23.87%	23.36B
ZIMMER BIOMET HOLDINGS, INC.	-1.04%	-3.63%	-6.97%	-13.91%	21.5B
STERIS PLC	-0.71%	-1.45%	+8.33%	-4.26%	21.31B
Average	-0.38%	-0.90%	+4.46%	+2.13%	59.29B
Weighted average by Cap.	-0.24%	-1.46%	+6.96%	-2.39%

	2025 *	2026 *
Net sales	1,021B 6.81B 6.45B 5.97B 5.34B 9.63B 577B 10.66B 74.35B 27.49B 237B 25.59B 25.02B	1,097B 7.32B 6.92B 6.42B 5.74B 10.34B 620B 11.45B 79.85B 29.52B 255B 27.48B 26.87B
Net income	131B 872M 825M 765M 684M 1.23B 73.85B 1.36B 9.52B 3.52B 30.34B 3.28B 3.2B	152B 1.01B 957M 887M 793M 1.43B 85.65B 1.58B 11.04B 4.08B 35.19B 3.8B 3.71B
Net Debt	-29.71B -198M -188M -174M -155M -280M -16.78B -310M -2.16B -800M -6.9B -744M -728M	-80.72B -538M -510M -472M -422M -761M -45.6B -843M -5.88B -2.17B -18.74B -2.02B -1.98B